Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 273 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Varenicline tartrate Clear all
Completed Phase 1 Interventional

Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use

NCT06027840
View directory record Official record
Conditions
Cigarette Smoking, E-Cigarette Use, Smoking Cessation
Interventions
Varenicline, Counseling, Guided Self-Change Booklets
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215
View directory record Official record
Conditions
Long Term Follow up Dry Eye Disease
Interventions
OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)

NCT05082974
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Vance Thompson Vision ND
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 13, 2026, 9:42 PM EDT
Recruiting Early Phase 1 Interventional

Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder

NCT06582888
View directory record Official record
Conditions
Nicotine Addiction, Craving
Interventions
Varenicline Tartrate, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Not applicable Interventional

Contingency Management to Promote Smoking Cessation

NCT06456242
View directory record Official record
Conditions
Smoking Cessation
Interventions
CounsCM+MedCM (Health Rewards)
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Varenicline Treatment for Cannabis Use Disorder

NCT02892110
View directory record Official record
Conditions
Substance Use Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 13, 2026, 9:42 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

NCT01560507
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Dependence
Interventions
varenicline (Chantix), bupropion (Zyban), nicotine patches
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence

NCT02202499
View directory record Official record
Conditions
Smoking Cessation, Tobacco Dependence
Interventions
Varenicline, Counseling and Support Materials, Laboratory Assessments
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Results available

Cannabis and Tobacco Co-use Study

NCT04228965
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Varenicline, Contingency Management, Counseling
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 40 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Charleston, South Carolina • Florence, South Carolina • Pickens, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Early Phase 1 Interventional Results available

Hollings Cancer Center Varenicline Sampling Study

NCT03742154
View directory record Official record
Conditions
Smoking, Smoking Cessation, Smoking, Tobacco, Smoking, Cigarette
Interventions
Varenicline 0.5 MG
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype

NCT00894166
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine Patches, Nicotine patches, then bupropion & nicotine patches (Pre-Quit), Nicotine patches, then varenicline (Pre-Quit), Nicotine patches, then nicotine patches (Pre-Quit), Nicotine patches, then bupropion & nicotine patches (Post-Quit), Nicotine patches, then varenicline (Post-Quit), Nicotine patches, then nicotine patches (Post-Quit)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Charlotte, Durham, Raleigh, Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

NCT04957758
View directory record Official record
Conditions
Neurotrophic Keratopathy
Interventions
OC-01 (varenicline) nasal spray 1.2 mg/ml, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 3 Interventional

A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline

NCT00143299
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
8
States / cities
Denver, Colorado • Milford, Massachusetts • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2007 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Results available

Varenicline Light Smoking Pilot

NCT04089982
View directory record Official record
Conditions
Smoking Cessation, Smoking Behaviors, Smoking
Interventions
Varenicline, Placebo oral tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 2 Interventional

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

NCT04634071
View directory record Official record
Conditions
Smoking Cessation, Cancer, Treatment-Related
Interventions
Varenicline, Bupropion, Long-acting nicotine replacement therapy, Low-intensity counseling, High-intensity counseling, No nicotine replacement therapy, Nicotine Replacement Products
Drug · Behavioral · Other
Lead sponsor
Joseph Valentino, MD
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Bowling Green, Kentucky • Lexington, Kentucky • Owensboro, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Results available

Varenicline Adjunctive Treatment in Schizophrenia

NCT00492349
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Varenicline and Bupropion for Smoking Cessation

NCT00935818
View directory record Official record
Conditions
Smoking
Interventions
Varenicline, placebo, bupropion SR
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
3
States / cities
Minneapolis, Minnesota • Rochester, Minnesota • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 13, 2026, 9:42 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Cannabis-Tobacco Co-Use Treatment Study

NCT06883162
View directory record Official record
Conditions
Tobacco Use Disorder, Tobacco Use Cessation, Cannabis Use, Cannabis Use Disorder, Marijuana Use
Interventions
Varenicline, Counseling, Psychosocial modules
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 13, 2026, 9:42 PM EDT
Terminated Phase 3 Interventional Results available

Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes

NCT02856581
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Varenicline, Placebo, Tobacco Cessation Counseling
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
374
States / cities
Fairbanks, Alaska • Kingman, Arizona • Jonesboro, Arkansas + 236 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 13, 2026, 9:42 PM EDT
Withdrawn Not applicable Interventional

Mood and Anti-craving Effects of Varenicline in Psychiatric Inpatients

NCT00525928
View directory record Official record
Conditions
Smoking, Depressive Disorder
Interventions
varenicline
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Results available

Smoking Cessation Treatment for Methadone Maintenance Patients

NCT01027754
View directory record Official record
Conditions
Smoking Cessation, Substance-Related Disorders
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 13, 2026, 9:42 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)

NCT05045508
View directory record Official record
Conditions
Dry Eye
Interventions
OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) Nasal Spray
Drug
Lead sponsor
Brandon Baartman
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Results available

New Approaches to Smoking Cessation in Heavy Drinkers

NCT02151591
View directory record Official record
Conditions
Nicotine Dependence, Cigarette Smoking, Alcohol Consumption, Heavy Drinking
Interventions
Varenicline
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 13, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence

NCT03538808
View directory record Official record
Conditions
Medication Adherence
Interventions
Varenicline, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 13, 2026, 9:42 PM EDT